Effect of interferon α-1b sequential Lamivudine combined therapy on T lymphocyte subsets, complement levels and liver function in children with chronic hepatitis B
LI Bo1 ZHENG Huanwei2▲ ZHAO Zhaoxia3 LI Jianxia4 XU Jianping5 JIN Peng6
1.Department of Pediatrics, Shijiazhuang Fifth Hospital, Hebei Province, Shijiazhuang 050024, China;
2.Department of Infectious Disease, Shijiazhuang Fifth Hospital, Hebei Province, Shijiazhuang 050024, China;
3.Department of Clinical Laboratory, Shijiazhuang Fifth Hospital, Hebei Province, Shijiazhuang 050024, China;
4.Department of Obstetrics and Gynecology, Pingshan County Hospital of Traditional Chinese Medicine, Hebei Province, Shijiazhuang 050400, China;
5.Department of Obstetrics and Gynecology, the Fifth Hospital of Shijiazhuang City, Hebei Province, Shijiazhuang 050024, China;
6.Department of Scientific Education, Shijiazhuang Fifth Hospital, Hebei Province, Shijiazhuang 050024, China
Abstract：Objective To investigate the effects of interferon α-1b sequential Lamivudine on the expression of T lymphocyte subsets and complement in children with chronic hepatitis B, and to evaluate liver function. Methods A total of 136 children with chronic hepatitis B admitted to the Shijiazhuang Fifth Hospital (“our hospital” for short) from November 2015 to December 2017 were selected as subjects. They were divided into study groups according to the random number table method, and 68 cases in each group. The control group received only intramuscular injection of interferon α-1b. The study group was treated with Lamivudine combined interferon α-1b. The T lymphocyte subsets (CD4+, CD8+, CD4+/CD8+), CD8+ T cell PD-1, Tim-3 expression, complement (C3, C4) levels were observed before and after treatment in two groups. The levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin (TBil) were observed before and after treatment in both groups. Results After treatment, the levels of CD4+, CD4+/CD8+ in the study group were higher than those in the control group, and the levels of CD8+ in the study group were lower than those in the control group (P < 0.05). After treatment, the levels of CD8+ T cell PD-1, CD8+ Tim-3 in the study group were lower than those in the control group, while the levels of C3 and C4 in the study group were higher than those in the control group (P < 0.05). After treatment, ALT, AST and TBil in the two groups were lower than those before treatment, and the differences between the study group and the control group were statistically significant (P < 0.05). Conclusion Lamivudine combined with interferon α-1b in the treatment of children with chronic hepatitis B can significantly improve the T lymphocyte subsets of children, HBV DNA, HBsAg, HBeAg levels are significantly improved, with significant anti-fibrosis effect.
李博1 郑欢伟2▲ 赵召霞3 李健霞4 许剑萍5 金鹏6. 干扰素■-1b序贯拉米夫定联合治疗对慢性乙型肝炎患儿T淋巴细胞亚群、补体水平及肝功能的影响[J]. 中国医药导报, 2019, 16(14): 148-151.
LI Bo1 ZHENG Huanwei2▲ ZHAO Zhaoxia3 LI Jianxia4 XU Jianping5 JIN Peng6. Effect of interferon α-1b sequential Lamivudine combined therapy on T lymphocyte subsets, complement levels and liver function in children with chronic hepatitis B. 中国医药导报, 2019, 16(14): 148-151.
[1] Nguyen TH，Vu MH，Nguyen VC，et al. A reduction inchronic hepatitis Bvirus infection prevalence among children in Vietnam demonstrates the importance of vaccination [J]. Vaccine，2014，32（2）：217-222.
[2] Abdel-Hady M，Kelly D. Chronic hepatitis B in children and adolescents：epidemiology and management [J]. Paediatr Drugs，2013，15（4）：311-317.
[3] El-Shabrawi M，Hassanin F. Treatment of hepatitis B and C in children [J]. Minerva Pediatr，2014，66（5）：473-489.
[4] Kekez AJ. Treatment of viral hepatitis in children [J]. Acta Med Croatica，2013，67（4）：303-309.
[5] Kas?覦rga E. Lamivudine resistance in children with chronic hepatitis B [J]. World J Hepatol，2015，7（6）：896-902.
[6] 王丽旻，张鸿飞，董漪，等.α干扰素治疗慢性乙型肝炎儿童对身高及体质量的影响[J].中华传染病杂志，2017， 35（1）：11-14.
[7] 孟庆华，侯维.2015年版《慢性乙型肝炎防治指南》——慢性乙型肝炎抗病毒治疗指南解读[J].中国全科医学，2016，19（14）：1613-1615.
[8] 李娅，王昕.肌内注射重组人干扰素-α1b致过敏性休克与急性重症荨麻疹[J].药物不良反应杂志，2017，19（4）：302-303.
[9] 刘逢仁，陈江平，池宏亮，等.用干扰素α2b联合拉米夫定对慢性乙型肝炎患者进行治疗的效果研究[J].当代医药论丛，2017，15（4）：30-31.
[10] 臧玮，田立峰，邱芳，等.聚乙二醇干扰素α-2a联合恩替卡韦治疗拉米夫定耐药的慢性乙型肝炎患者疗效分析[J].实用肝脏病杂志，2017，20（3）：350-351.
[11] 娄海泉.拉米夫定联合聚乙二醇干扰素治疗慢性乙型肝炎合并脂肪肝疗效分析[J].淮海医药，2017，35（3）：342-344.
[12] 李国云，孟丽萍，季雪良，等.拉米夫定耐药对α-2a干扰素HBeAg阳性慢性乙型肝炎疗效的影响[J].临床医药文献电子杂志，2017，4（42）：8294-8295.
[13] 朱红欣.拉米夫定联合重组人干扰素α-2b治疗慢性乙型病毒性肝炎的临床疗效[J].中国现代医生，2017， 55（3）：89-91.
[14] 叶鹏，王志杰，廖化波.聚乙二醇干扰素α-2a联合阿德福韦酯对HBeAg阳性慢性乙肝患者细胞免疫功能影响[J].慢性病学杂志，2017，2（6）：633-637.
[15] 阿力木江·毛拉艾沙，布力布力·马那甫，古丽加孜依拉，等.不同用药方案治疗HBeAg阳性慢性乙型肝炎的效果及对血清IFN-γ、IL-10的影响[J].中国医药导报，2017，14（5）：137-140，156.
[16] 方楚葵.恩替卡韦治疗拉米夫定耐药的慢性乙型肝炎的疗效及安全性[J].中国医药科学，2017，7（19）：68-70.
[17] 李亚萍.α-干扰素联合恩替卡韦治疗慢性乙型肝炎的临床效果观察[J].临床和实验医学杂志，2017，16（12）：1190-1192.
[18] 王雪洁，杜凤霞，于珊珊，等.治疗慢性乙型病毒性肝炎的中药注射剂及其部分药品不良反应回顾性分析[J].中国医院用药评价与分析，2017，17（1）：13-15.
[19] 何璇，杨玉雪，建霞，等.六味五灵片与核苷酸类似物联合治疗慢性乙型病毒性肝炎的系统评价[J].中国医院用药评价与分析，2017，17（1）：1-6，9.
[20] 樊正勤，曹灵芝，赵耘，等.核苷类似物干预后慢性乙型肝炎患者HBV多聚酶区基因突变模式与危险因素分析[J].实用临床医药杂志，2017，21（5）：54-56.
[21] 鲍旭丽，渠亚超，熊芳，等.聚乙二醇干扰素联合核苷（酸）类似物96周延长疗程治疗e抗原阳性慢性乙型肝炎患者的效果观察[J].中国综合临床，2016，32（8）：673-676.
[22] 杨栋强，陈芳，康谊，等.拉米夫定耐药后联合阿德福韦酯治疗发生再耐药的慢性乙型肝炎患者的基因型及耐药位点分析[J].临床肝胆病杂志，2016，32（3）：480-483.
[23] 陈端.拉米夫定在慢性乙型肝炎患儿外周血Th17细胞变化的研究[J].检验医学与临床，2016，13（9）：1220-1221.
[24] 臧玮，田立峰，邱芳，等.拉米夫定耐药e抗原阳性乙型肝炎应用恩替卡韦或阿德福韦酯联合聚乙二醇干扰素α-2a的疗效评价[J].肝脏，2016，21（11）：943-945.
[25] 李忠斌，邵清，李梵，等.替诺福韦酯单独与联合恩替卡韦挽救治疗恩替卡韦治疗拉米夫定经治慢性乙型肝炎失败患者疗效比较[J].肝脏，2016，21（3）：165-167.
2019, Vol. 16 
京公网安备 11010502046598号